Literature DB >> 30662656

RNA binding motif protein 3 (RBM3) drives radioresistance in nasopharyngeal carcinoma by reducing apoptosis via the PI3K/AKT/Bcl-2 signaling pathway.

Rui Ma1, Li-Na Zhao1, Hua Yang1, Yan-Fei Wang2, Jing Hu1, Jian Zang1, Jian-Guo Mao1, Jing-Jing Xiao3, Mei Shi1.   

Abstract

Radioresistance is an important obstacle to nasopharyngeal carcinoma (NPC) therapy. In this study, we explored the role of RNA-binding motif protein 3 (RBM3) in the radioresistance of NPC and its underlying mechanism. We measured the expression of RBM3 in 20 clinical NPC tissues and in NPC cell lines. We found that RBM3 was upregulated in radioresistant NPC tissues and cells. Radioresistant NPC cells (CNE1/IR) and parental NPC cells (CNE1) were subjected to RBM3-shRNA knockdown and RBM3 overexpression, respectively. RBM3 depletion in CNE1/IR cells sensitized cells to radiotherapy, increased DNA damage, and accelerated the rate of apoptosis. In contrast, RBM3 overexpression in CNE1 cells significantly enhanced radioresistance and reduced the rate of apoptosis. Additionally, radioresistance conferred by RBM3 was attributed to the activation of the AKT/Bcl-2 signaling pathway and reduction of caspase 3. Inhibition of AKT signaling attenuated RBM3-mediated radioresistance. Furthermore, RBM3 directly interacted with PI3K subunit p85 in NPC cell lines. Altogether, our data demonstrate that RBM3 enhances radioresistance by inhibiting the apoptotic response to radiotherapy through the PI3K/AKT/Bcl-2 signaling pathway. RBM3 may serve as a novel factor for predicting radioresistance and as a molecular target in the treatment of NPC.

Entities:  

Keywords:  Bcl-2; PI3K; RBM3; apoptosis; nasopharyngeal carcinoma; radioresistance

Year:  2018        PMID: 30662656      PMCID: PMC6325530     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  8 in total

1.  RBM3 interacts with Raptor to regulate autophagy and protect cardiomyocytes from ischemia-reperfusion-induced injury.

Authors:  Nan Wang; Limeiting Wang; Changyan Li; Peng Rao; Xun Wang; Yazhou Xu; Lin Yang; Lin Sun; Di Lu
Journal:  J Physiol Biochem       Date:  2022-10-04       Impact factor: 5.080

2.  RNA binding motif protein 3 (RBM3) promotes protein kinase B (AKT) activation to enhance glucose metabolism and reduce apoptosis in skeletal muscle of mice under acute cold exposure.

Authors:  Yang Liu; Hongzhao Shi; Yajie Hu; Ruizhi Yao; Peng Liu; Yuying Yang; Shize Li
Journal:  Cell Stress Chaperones       Date:  2022-09-23       Impact factor: 3.827

3.  Age-related responses to a bout of mechanotherapy in skeletal muscle of rats.

Authors:  Douglas W Van Pelt; Amy L Confides; Sarah M Abshire; Emily R Hunt; Esther E Dupont-Versteegden; Timothy A Butterfield
Journal:  J Appl Physiol (1985)       Date:  2019-10-31

4.  MiR-27a promotes the autophagy and apoptosis of IL-1β treated-articular chondrocytes in osteoarthritis through PI3K/AKT/mTOR signaling.

Authors:  Chen Cai; Shaoxiong Min; Bo Yan; Wen Liu; Xiao Yang; Liuxun Li; Ting Wang; Anmin Jin
Journal:  Aging (Albany NY)       Date:  2019-08-27       Impact factor: 5.682

5.  Transcriptomic Analyses Reveal Gene Expression Profiles and Networks in Nasopharyngeal Carcinoma.

Authors:  Yaqi Zhou; Weiqiang Yang; Xueshuang Mei; Hongyi Hu
Journal:  Biomed Res Int       Date:  2021-01-25       Impact factor: 3.411

6.  Inhibition of cell proliferation and radioresistance by miR-383-5p through targeting RNA binding protein motif (RBM3) in nasopharyngeal carcinoma.

Authors:  Rui Ma; Peng Gao; Hua Yang; Jing Hu; Jing-Jing Xiao; Mei Shi; Li-Na Zhao
Journal:  Ann Transl Med       Date:  2021-01

Review 7.  Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma.

Authors:  Yuanbo Kang; Weihan He; Caiping Ren; Jincheng Qiao; Qiuyong Guo; Jingyu Hu; Hongjuan Xu; Xingjun Jiang; Lei Wang
Journal:  Signal Transduct Target Ther       Date:  2020-10-23

Review 8.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.